2025 SID Annual Meeting Coverage: Artax Biopharma’s Oral Nck Modulator Shows Promise in PsO
Artax Biopharma’s oral Nck modulator AX-158 performed well in a Phase 2a study of patients with mild-to-moderate plaque psoriasis.
Tag: Nck
Artax Biopharma’s oral Nck modulator AX-158 performed well in a Phase 2a study of patients with mild-to-moderate plaque psoriasis.